BioCentury
ARTICLE | Company News

Medigene, Nordic Group sales and marketing update

December 10, 2012 8:00 AM UTC

Nordic's Nordic Pharma received exclusive rights to commercialize Veregen to treat genital warts in the Czech Republic, Slovakia, Poland, Hungary, Baltic countries, Georgia and the Commonwealth of Independent States (CIS). Medigene is eligible for milestones, double-digit royalties and payments related to the manufacture and supply of the product. Nordic, which is responsible for regulatory activities in the regions, plans to launch Veregen in the Czech Republic, Slovakia, Poland and Hungary next year. Marketing applications for the other countries are "in preparation," but Medigene declined to disclose a timeline. ...